Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
Globe Newswire•18/11/2026•07:50 ET
1
Key Highlights
- ➤36 claims cover twice-daily stenoparib dosing in ovarian cancer and other solid tumors
- ➤Patent protection for stenoparib dosing regimen extends into 2045
- ➤Allarity’s ongoing Phase 2 program uses the twice-daily dosing strategy
- ➤Separate Phase 2 stenoparib-temozolomide trial began enrolling relapsed SCLC patients in early 2026
Expert Statements
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval”
Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors
Strengthens intellectual property supporting the dosing strategy used in the Company's ongoing Phase 2 program
Get started
Create a free account to read the full story.
